LUXEMBOURG–(BUSINESS WIRE)–Regulatory News:

Eurofins (Paris:ERF):

Eurofins Scientific (EUFI.PA), one of the world leaders in genomic
services, and Weatherbys Ireland DNA Laboratories, one of Ireland’s
premier laboratories serving the domestic agri-industry, are pleased to
announce that they have been jointly selected to test one million
samples of beef for the Irish Cattle Breeding Federation (ICBF) over the
next two years.

The ambitious project is the first anywhere in the world to genotype one
million cattle. The test itself uses a microarray technology to measure
55,000 variable positions in the DNA of each animal. From this,
scientists will use this information to predict traits such as
fertility, milk yield and meat quality in individual animals. The work
is part of the Beef Data Genomics Program (BDGP), running from 2015 to
2020, launched earlier this year by Ireland’s Minister for Agriculture
Food and Marine, Simon Coveney, TD. The ICBF is aiming to genotype one
million cattle by 2017, and a further million by 2020.

Comment from Ronan Murphy, Weatherbys CEO: “This project is a huge step
forward in agri-genomics and we are delighted to have been selected to
carry out a testing regime that has never been done on this scale
before. The microarray chip we will be using has taken two years of
development by Weatherbys Ireland DNA laboratory, the ICBF and Teagasc
(Irish agriculture and food development authority). By teaming up with
Eurofins Genomics, we are able to provide expertise and accredited
laboratories at the scale needed to provide customers with new and more
efficient services for their animal breeding needs.”

Comment from Bruno Poddevin, Senior Vice President, Eurofins Genomic
Services: “Eurofins Genomics is proud and delighted to have been
selected, together with Weatherbys’ DNA Laboratory, to provide its
expertise in the world’s largest cattle genotyping project-to-date.
Through our combined industrial capabilities and highly-skilled DNA
experts, Eurofins aims to provide customers in the food and
agri-genomics markets the highest quality and most cost-efficient
solutions for their animal-breeding needs. We are excited to provide our
unparalleled capabilities and lend our expertise in large-scale project,
and help put Ireland and its farmers at the forefront of genetic testing
globally”.

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific is the world leader in food, environment and
pharmaceutical products testing. It is also one of the global market
leaders in agroscience, genomics, discovery pharmacology and central
laboratory services. In addition, Eurofins is one of the key emerging
players in specialty clinical diagnostic testing in Europe and the USA.

With 20,000 staff in around 200 laboratories across 39 countries,
Eurofins offers a portfolio of over 130,000 reliable analytical methods
for evaluating the safety, identity, composition, authenticity, origin
and purity of biological substances and products, as well as for
innovative clinical diagnostic. The Group provides its customers with
high-quality services, accurate results on time and expert advice by its
highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through RD and acquisitions, the Group draws on the latest developments
in the field of biotechnology and analytical chemistry to offer its
clients unique analytical solutions and the most comprehensive range of
testing methods.

As one of the most innovative and quality oriented international players
in its industry, Eurofins is ideally positioned to support its clients’
increasingly stringent quality and safety standards and the expanding
demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock
Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates
that involve risks and uncertainties. The forward-looking statements and
estimates contained herein represent the judgement of Eurofins
Scientific’ management as of the date of this release. These
forward-looking statements are not guarantees for future performance,
and the forward-looking events discussed in this release may not occur.
Eurofins Scientific disclaims any intent or obligation to update any of
these forward-looking statements and estimates. All statements and
estimates are made based on the data available to the Company as of the
date of publication, but no guarantee can be made as to their validity.